2024
Optimization criteria for ordering myeloid neoplasm next‐generation sequencing
Gisriel S, Howe J, Tormey C, Torres R, Hager K, Rinder H, Siddon A. Optimization criteria for ordering myeloid neoplasm next‐generation sequencing. EJHaem 2024 DOI: 10.1002/jha2.1036.Peer-Reviewed Original ResearchNext-generation sequencingNext-generation sequencing testMyeloid neoplasmsDiagnosis of chronic myeloid leukemiaAltering treatment plansEnd-of-inductionFluorescence in situ hybridizationRecurrence post-transplantChronic myeloid leukemiaSuspicion of progressionPathogenic mutationsClinical suspicionMutation statusMN diagnosisMyeloid leukemiaPost-transplantRisk stratificationWorsening diseaseTreatment planningCancellation criteriaSuspicionDiagnosisSequenceCenters for MedicareB testMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftment
2023
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon A, Weinberg O. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics In Laboratory Medicine 2023, 43: 607-614. PMID: 37865506, DOI: 10.1016/j.cll.2023.07.004.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeTP53 mutationsPrognosis of MDSCases of MDSPrognostic scoring systemNext-generation sequencingParticular next-generation sequencingAggressive diseasePoor outcomeTherapeutic managementTP53 disruptionMyeloid leukemiaMyeloid neoplasmsTherapeutic advancementsCytogenetic abnormalitiesMyeloid neoplasiaScoring systemDisease classificationMyeloid diseasesGene mutationsSyndromeDiseaseDiagnosisTP53Molecular findings in myeloid neoplasms
Tran T, Siddon A. Molecular findings in myeloid neoplasms. International Journal Of Laboratory Hematology 2023, 45: 442-448. PMID: 37345257, DOI: 10.1111/ijlh.14118.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid neoplasmsNext-generation sequencingMyeloproliferative neoplasmsInternational diagnostic guidelinesSomatic gene mutationsHematologic cancersMyeloid leukemiaDiagnostic guidelinesClinical relevanceMyeloid disordersPatient careNeoplasmsCytogenetic findingsMolecular findingsGene mutationsNew molecular technologiesMolecular technologiesMutationsLeukemiaCancerPrognosticationCliniciansFindingsModifier mutationsOptimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative threshold
2022
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype
Ramia de Cap M, Wu L, Pihan G, Narayanan D, Morgan E, Pinkus G, Cin P, Hurwitz S, Bagg A, Patel S, Tam W, Ouseph M, Gagan J, Madanat Y, Siddon A, Raess P, Rogers H, Bueso-Ramos C, Kanagal-Shamanna R, Kurzer J, Arber D, Hasserjian R, Weinberg O. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leukemia Research 2022, 123: 106965. PMID: 36332291, DOI: 10.1016/j.leukres.2022.106965.Peer-Reviewed Original ResearchAutomated analysers underestimate atypical basophil count in myeloid neoplasms
Shah HP, Tormey CA, Siddon AJ. Automated analysers underestimate atypical basophil count in myeloid neoplasms. International Journal Of Laboratory Hematology 2022, 44: 831-836. PMID: 35609868, DOI: 10.1111/ijlh.13882.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsBasophil percentageBasophil countsMyeloproliferative neoplasmsManual differentialMyeloid disordersFlow cytometryTertiary care centerChronic myeloid leukemiaMyeloid neoplasms patientsControl patientsMyelodysplastic diseasesMean ageNeoplasm patientsControl subjectsCare centerMyeloid leukemiaPatientsNeoplasmsAtypical appearanceScatter propertiesMyeloid diseasesBasophilsDisorder diagnosisCytometry
2021
Behind the scenes with basophils: an emerging therapeutic target
Shah H, Eisenbarth S, Tormey CA, Siddon AJ. Behind the scenes with basophils: an emerging therapeutic target. Immunotherapy Advances 2021, 1: ltab008. PMID: 35919744, PMCID: PMC9327101, DOI: 10.1093/immadv/ltab008.Peer-Reviewed Original ResearchChronic myeloid leukemiaImmunoregulatory functionsMyeloproliferative neoplasmsType 2 cytokinesCD4 T cell differentiationDevelopment of immunotherapyNon-malignant diseasesT cell differentiationB cell activationBasophil biologyMalignant disease statesAllergic inflammationInflammatory mediatorsBasophil degranulationPeripheral bloodAllergic responsesIL-4Th2 cellsAberrant immunophenotypeMyeloid leukemiaAdaptive immunityHematological malignanciesMast cellsMyeloid neoplasmsDiagnostic criteria
2020
How I Diagnose Low-Grade Myelodysplastic Syndromes
Siddon AJ, Hasserjian RP. How I Diagnose Low-Grade Myelodysplastic Syndromes. American Journal Of Clinical Pathology 2020, 154: 5-14. PMID: 32458977, DOI: 10.1093/ajcp/aqaa046.Peer-Reviewed Original ResearchConceptsLow-grade myelodysplastic syndromesMyelodysplastic syndromeMorphologic dysplasiaPeripheral blood cytopeniasCauses of cytopeniaDifficult diagnostic dilemmaBone marrow morphologyClonal genetic abnormalitiesRole of pathologistsBlood cytopeniasPeripheral bloodClinical recordsDiagnostic dilemmaMarrow morphologySecondary causesAncillary studiesIneffective hematopoiesisMyeloid neoplasmsMDS casesClinical heterogeneityDiagnostic algorithmResults of cytogeneticsGenetic abnormalitiesClonal hematopoiesisIndeterminate potential